GlycoMimetics Reports Agreement Termination & Director Changes

Ticker: CBIO · Form: 8-K · Filed: Feb 25, 2025 · CIK: 1253689

Glycomimetics INC 8-K Filing Summary
FieldDetail
CompanyGlycomimetics INC (CBIO)
Form Type8-K
Filed DateFeb 25, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: agreement-termination, corporate-governance, management-change

TL;DR

GlycoMimetics terminated a key deal and shuffled its board. Big changes ahead.

AI Summary

GlycoMimetics, Inc. reported on February 19, 2025, the termination of a material definitive agreement and changes in its board of directors and officer compensation. The company, incorporated in Delaware, is based in Rockville, Maryland.

Why It Matters

This filing indicates significant corporate governance and contractual shifts for GlycoMimetics, potentially impacting its strategic direction and operational agreements.

Risk Assessment

Risk Level: medium — Termination of material agreements and changes in leadership can signal underlying business challenges or strategic realignments that carry inherent risks.

Key Players & Entities

FAQ

What was the specific material definitive agreement that was terminated?

The filing states the termination of a material definitive agreement but does not specify which agreement was terminated.

What were the reasons for the termination of the material definitive agreement?

The filing does not provide the reasons for the termination of the material definitive agreement.

Were there any specific directors or officers whose departure was reported?

The filing indicates 'Departure of Directors or Certain Officers' as an item, but does not name specific individuals in the provided text.

What changes were made to compensatory arrangements of certain officers?

The filing lists 'Compensatory Arrangements of Certain Officers' as an item, but does not detail the specific changes in the provided text.

What is the SIC code for GlycoMimetics, Inc.?

The Standard Industrial Classification (SIC) code for GlycoMimetics, Inc. is 2834, Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on February 25, 2025 regarding GLYCOMIMETICS INC (CBIO).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing